Vallon Pharmaceuticals, Inc. announced that Penny S. Toren's position as Senior Vice President, Regulatory Affairs & Project Management was eliminated, effective immediately, as part of the Company's effort to streamline its operations in order to preserve its capital and cash resources and not as the result of any disagreement with the Company on any matter relating to the Company's operations, policies or practices or in any way for cause. The Company continues to work with its existing outside regulatory consultants to manage all submissions to and interactions with regulatory agencies, including the U.S. Food and Drug Administration.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.2899 USD | +0.31% | -7.97% | -95.67% |
04-16 | GRI Bio Receives South Korea Patent for Liver Inflammatory Condition Treatments | MT |
2023 | Vallon Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023 | CI |
- Stock Market
- Equities
- GRI Stock
- News GRI BIOPAR
- Vallon Pharmaceuticals, Inc. Announces Elimination of Penny S. Toren as Senior Vice President